TY - JOUR
T1 - Descemet Stripping Endothelial Keratoplasty for Fuchs' Endothelial Corneal Dystrophy
T2 - Five-Year Results of a Prospective Study
AU - Wacker, Katrin
AU - Baratz, Keith H.
AU - Maguire, Leo J.
AU - McLaren, Jay W.
AU - Patel, Sanjay V.
N1 - Funding Information:
Supported by Research to Prevent Blindness, Inc., New York, New York (unrestricted grant to the Department of Ophthalmology and support to S.V.P. as Olga Keith Wiess Special Scholar); Dr. Werner Jackstaedt-Stiftung Foundation, Wuppertal, Germany (Research Fellowship to K.W.); and Mayo Foundation, Rochester, Minnesota. The funding organizations had no role in the design or conduct of this research
Publisher Copyright:
© 2016 American Academy of Ophthalmology.
Copyright:
Copyright 2015 Elsevier B.V., All rights reserved.
PY - 2016/1/1
Y1 - 2016/1/1
N2 - To determine 5-year outcomes of Descemet stripping endothelial keratoplasty (DSEK) for Fuchs' endothelial corneal dystrophy (FECD). Design Prospective cohort study. Participants Fifty-two eyes of 45 subjects with FECD undergoing primary DSEK. Methods Subjects were examined before and at fixed intervals through 60 months after DSEK. At each visit, graft survival was determined by slit-lamp examination; best spectacle-corrected visual acuity (BSCVA) was measured using the electronic Early Treatment Diabetic Retinopathy Study (ETDRS) protocol; total anterior corneal higher-order aberrations (HOAs) were derived from corneal topography; and corneal backscatter, corneal thickness, and endothelial cell density were measured from confocal microscopy images. Corneal thickness also was measured by ultrasonic pachymetry. Changes after DSEK were analyzed using generalized estimating equation models. Main Outcome Measures Best-corrected visual acuity, HOAs, endothelial cell loss, corneal thickness, and corneal backscatter. Results Complete 60-month follow-up was possible in 34 eyes. Mean BSCVA ± standard deviation improved from 0.45 ± 0.19 logarithm of the minimum angle of resolution (logMAR) (Snellen equivalent, 20/56) before DSEK to 0.09 ± 0.13 logMAR (Snellen equivalent, 20/25) at 5 years (P < 0.001). Between 1 and 5 years, BSCVA improved by 0.06 logMAR (or 3 ETDRS letters; 95% confidence interval, 0.05-0.07 logMAR) per year (P < 0.001), and 56% of eyes were 0.1 logMAR (20/25) or better at 5 years. Graft thickness (approximately 155 μm) and corneal thickness (approximately 700 μm) did not change after surgery. Anterior corneal HOAs and backscatter decreased between 1 and 5 years (P ≤ 0.002). Six grafts failed, of which 4 were primary (iatrogenic); mean endothelial cell loss ± standard deviation was 55±15% at 5 years. Conclusions Between 1 and 5 years after DSEK, BSCVA continues to improve such that at 5 years, more than half of eyes see better than 20/25 with a mean total corneal thickness of 700 μm. Improvement in vision is accompanied by continued reduction in corneal haze and aberrations, suggesting ongoing remodeling of the cornea after restoration of endothelial function.
AB - To determine 5-year outcomes of Descemet stripping endothelial keratoplasty (DSEK) for Fuchs' endothelial corneal dystrophy (FECD). Design Prospective cohort study. Participants Fifty-two eyes of 45 subjects with FECD undergoing primary DSEK. Methods Subjects were examined before and at fixed intervals through 60 months after DSEK. At each visit, graft survival was determined by slit-lamp examination; best spectacle-corrected visual acuity (BSCVA) was measured using the electronic Early Treatment Diabetic Retinopathy Study (ETDRS) protocol; total anterior corneal higher-order aberrations (HOAs) were derived from corneal topography; and corneal backscatter, corneal thickness, and endothelial cell density were measured from confocal microscopy images. Corneal thickness also was measured by ultrasonic pachymetry. Changes after DSEK were analyzed using generalized estimating equation models. Main Outcome Measures Best-corrected visual acuity, HOAs, endothelial cell loss, corneal thickness, and corneal backscatter. Results Complete 60-month follow-up was possible in 34 eyes. Mean BSCVA ± standard deviation improved from 0.45 ± 0.19 logarithm of the minimum angle of resolution (logMAR) (Snellen equivalent, 20/56) before DSEK to 0.09 ± 0.13 logMAR (Snellen equivalent, 20/25) at 5 years (P < 0.001). Between 1 and 5 years, BSCVA improved by 0.06 logMAR (or 3 ETDRS letters; 95% confidence interval, 0.05-0.07 logMAR) per year (P < 0.001), and 56% of eyes were 0.1 logMAR (20/25) or better at 5 years. Graft thickness (approximately 155 μm) and corneal thickness (approximately 700 μm) did not change after surgery. Anterior corneal HOAs and backscatter decreased between 1 and 5 years (P ≤ 0.002). Six grafts failed, of which 4 were primary (iatrogenic); mean endothelial cell loss ± standard deviation was 55±15% at 5 years. Conclusions Between 1 and 5 years after DSEK, BSCVA continues to improve such that at 5 years, more than half of eyes see better than 20/25 with a mean total corneal thickness of 700 μm. Improvement in vision is accompanied by continued reduction in corneal haze and aberrations, suggesting ongoing remodeling of the cornea after restoration of endothelial function.
UR - http://www.scopus.com/inward/record.url?scp=84951084340&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84951084340&partnerID=8YFLogxK
U2 - 10.1016/j.ophtha.2015.09.023
DO - 10.1016/j.ophtha.2015.09.023
M3 - Article
C2 - 26481820
AN - SCOPUS:84951084340
SN - 0161-6420
VL - 123
SP - 154
EP - 160
JO - Ophthalmology
JF - Ophthalmology
IS - 1
ER -